Volume 7 Supplement 1

20th Brazilian Diabetes Society Congress

Open Access

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients

  • Paula Vieira Freire1Email author,
  • Erika Bezerra Parente1,
  • Cristal Peters Cabral1,
  • Andre Carvalho Yamaya1,
  • Caroline Schnoll1,
  • Vivian Roberta Ferreia Simões1,
  • Alessandra Muto1,
  • Manoel Carlos Sampaio de Almeida Ribeiro1 and
  • João Eduardo Nunes Salles1
Diabetology & Metabolic Syndrome20157(Suppl 1):A66

https://doi.org/10.1186/1758-5996-7-S1-A66

Published: 11 November 2015

Background

It is a common practice to administer basal insulin after oral diabetes agents fail as a first step in insulinization. However, we do not know which regime is better regarding glycemic control: adding basal insulin to sulfonylurea or stopping sulfonylurea and starting a basal bolus regime.

Objective

To compare glycemic variability in T2D patients being treated with two different regimes of diabetes treatment: basal insulin plus sulfonylurea versus basal bolus.

Materials and methods

A retrospective study of a cohort of 51 T2D patients. To evaluate glycemic variability, we collected data from glucometers (accu check 360 software was used to download the data) of all patients that came for physician's appointments at a public hospital between March and June 2015. We analyzed data of mean capillary glucose and its variability (standard deviation) from the 90-day period preceding the final download date. Glycemia and hba1c were also used for this analysis. Chi-square tests and student's t-test were performed for statistical analysis, where p < 0.05 was considered significant.

Results

Of the 417 patients included in this study, 51 were eligible for analysis. 11 patients were using insulin plus sulfonylurea (group 1) and 40 were using basal bolus treatment (group 2). The proportion of men and women in each group was 45.5%: 54.5% in group 1 and 32.5%: 67.5% in group 2 (Pearson chi-square p=0.42). There was no difference between treatments regarding A1c and glucose variability (Figure 1).
Figure 1

Results for both groups.

Conclusion

Sulfonylurea plus basal insulin and basal bolus had the same glucose control and glycemic variability in both patient sample groups.

Authors’ Affiliations

(1)
Santa Casa de Misericordia de São Paulo

Copyright

© Freire et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement